In the Drug Profile by Denis Raccah, ‘Efficacy and safety of lixisenatide in the treatment of Type 2 diabetes mellitus: a review of Phase III clinical data’, published in the March 2013 issue of Expert Review of Endocrinology and Metabolism (Expert Rev. Endocrinol. Metab. 8[2], 105–121 [2013]), on page 117, the following sentence appeared as:
“Given the effectiveness of basal insulin therapy in the majority of patients [60] and the relative simplicity of adding a GLP-1 receptor agonist to existing basal insulin (as evidenced in the GetGoal program), initiating injectable therapy with basal insulin in patients who are not achieving adequate glycemic control on basal insulin due to PPG would appear to be a rational approach for many patients.”
The sentence should have read:
“Given the effectiveness of basal insulin therapy in the majority of patients [60] and the relative simplicity of adding a GLP-1 receptor agonist to existing basal insulin (as evidenced in the GetGoal program), initiating injectable therapy with a GLP-1 receptor agonist in patients who are not achieving adequate glycemic control on basal insulin due to PPG would appear to be a rational approach for many patients.”
The authors and editors of Expert Review of Endocrinology and Metabolism would like to sincerely apologize for any inconvenience or confusion this may have caused our readers.